Mind Medicine MindMed Inc (MNMD) Options

Not concerned. I know we will be. This will be some of the biggest headlines when it happens.

We're going to be on the better side of history with this 

No, that is still very much in play.

This was the final stretch we've waited for. Hang tight. We have arrived. Let it steep. We are in for a strong ramp once CMSP read outs happen in June. Once that happens. Organic rise to the big wave.

Wait! A couple of more years?

So, I guess the $30-$40 billlion buyout by this June that you predicted is off the table? Imagine that! LMAO

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173524304

Looks like you're in for another ENZC ride here, Jack! lol How did holder yer shares work out for you there?

You've learned nothing from that, obviously!

It's gonna be a good next couple years. MM120 is gonna be approved, probably for both conditions. This will lead to other approvals down the road.

HOLD YER SHARES!!!

MindMed’s Bet on Psychedelic Psychiatry: Vanguards of Health Care

https://www.bloomberg.com/news/audio/2025-04-24/mindmed-s-bet-on-psychedelic-therapy-vanguards-of-health-care?srnd=homepage-americas

Check out this: https://www.reddit.com/r/MindMedInvestorsClub/comments/1k6g4ae/mnmd_schedule_14a_information_proxy_statement/

MNMD - SCHEDULE 14A INFORMATION - Proxy Statement Notes

Skimming through the new proxy (14A) from MindMed, I noticed something worth sharing, especially for those of us watching for long-term value or potential M&A action.

In Proposal No. 3 (page 34), which outlines the 2025 Equity Incentive Plan, there’s a line that stood out:

“A ‘liberal’ change in control definition (e.g., mergers require actual consummation) is not included.”

What this means in plain English: MindMed is using a stricter definition of “Change in Control.” Executives don’t get perks just because a deal is announced or a merger agreement is signed. They only benefit if and when the deal actually closes.

This is known as avoiding a “liberal” change in control definition. More liberal definitions let insiders cash in early — like just from a signed agreement or a change in board seats. That’s not the case here.

Instead, MindMed is requiring actual completion of a merger or acquisition before any bonuses or early stock vesting kick in. This protects investors from dilution or executive windfalls tied to deals that never even happen.

Why this matters (especially for retail investors like us):

It avoids premature executive payouts.

It shows smart governance — aligning leadership incentives with real shareholder value.

It might be a sign the company is positioning itself for possible future interest (acquisition, partnership, etc.), but doing it the right way.

To be clear — this doesn’t guarantee an M&A deal is coming. But it’s the kind of language that often appears when a company is tightening up its structure in preparation for something. Could be Phase 3 momentum, could be something bigger. Either way, the setup is solid.

Bottom line: This is investor-friendly language. And it’s refreshing to see a microcap biotech doing things by the book, instead of padding exec pay with low bars. Worth keeping an eye on.

MNMD is now considered a late Stage bio company. Hold. We are close.

All 3 Phase 3 Trials are active. Let's ride!

MindMed Announces First Patient Dosed in Phase 3 Emerge Study of MM120 in Major Depressive Disorder (MDD)

https://www.businesswire.com/news/home/20250414503827/en/MindMed-Announces-First-Patient-Dosed-in-Phase-3-Emerge-Study-of-MM120-in-Major-Depressive-Disorder-MDD

I am not a fan of what is going on. No one is really. However, there are some silver linings here.

Despite concerns around potential pharmaceutical tariffs, these recent developments might actually create significant opportunities for companies like MindMed. Rather than negatively impacting the sector, tariffs could reshape the pharmaceutical landscape in ways that positively benefit innovative, US-focused firms.

Key points highlighting the positive potential for MindMed include:

Enhanced Investment Flow: European uncertainty could redirect substantial pharma capital to the U.S., boosting investor interest and financial backing for innovative American biotech firms like MindMed.
Reduced Competition: Tariffs could discourage European competitors from quickly expanding into the U.S., giving MindMed more space and time to establish leadership in novel therapeutic areas.

Improved Industry Environment: Increased domestic pharmaceutical activity could lead to stronger industry infrastructure, talent availability, and accelerated regulatory support, benefiting MindMed’s product development and commercialization efforts.

Ultimately, rather than succumbing to tariff-related fear, uncertainty, and doubt (FUD), investors might recognize this as an opportunity for MindMed to strengthen its competitive advantage and benefit from renewed focus and investment in U.S.-based pharmaceutical innovation.

its margin calls

Yes, Mom, it has nothing directly to do with MNMD but it is crushing our stock price. Good luck with your catch a falling knife philosophy. This stock was struggling before Depression Don worked his magic and has only accelerated downward since.

What is happening is not good for any developmental biotech.

It's fear.

This has nothing to do with MindMed... f anything all this makes them more valuable. The economy is tanking due to the administration. I got a nice chuck at down on that giant dip.

people are forced to sell what is liquid

I don’t know about y’all but I’m getting tired of all this winning.

Synergistic air pollution exposure elevates depression risk: A cohort study

Depression is a leading mental health disorder worldwide, contributing substantially to the global disease burden. While emerging evidence suggests links between specific air pollutants and depression, the potential interactions among multiple pollutants remain underexplored. Here we show the influence of six common air pollutants on depressive symptoms among middle-aged and older Chinese adults. In single-pollutant models, a 10 mgm3 increase in SO2, CO, PM10, and PM2.5 is associated with increased risks of depressive symptoms, with odds ratios (95% confidence intervals) of 1.276 (1.238e1.315), 1.007 (1.006e1.008), 1.066 (1.055e1.078), and 1.130 (1.108e1.153), respectively. In two-pollutant models, SO2 remains significantly associated with depressive symptoms after adjusting for other pollutants. Multipollutant models uncover synergistic effects, with SO2, CO, NO2,PM10,andPM2.5 exhibiting significant interactions, identifying SO2 as the primary driver of these associations. Mediation analyses further indicate that cognitive and physical impairments partially mediate the relationship between air pollution and depressive symptoms. These findings underscore the critical mental health impacts of air pollution and highlight the need for integrated air quality management strategies. Targeted mitigation of specific pollutants, particularly SO2, is expected to significantly enhance public mental health outcomes. ©2024 The Authors. Published by Elsevier B.V. on behalf of Chinese Society for Environmental Sciences, Harbin Institute of Technology, Chinese Research Academy of Environmental Sciences. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Trump Stalls Cannabis Reform, Plus Mindmed CEO's 2025 Outlook | Trade to BLack - Dale's Report

Doug Collins - United States Secretary of Veterans Affairs | SRS #187

Trump’s Veterans Secretary Had ‘Eye-Opening’ Psychedelics Talk With RFK Jr.—And He Plans To Press Congress To Act

https://www.marijuanamoment.net/trumps-veterans-secretary-had-eye-opening-psychedelics-talk-with-rfk-jr-and-he-plans-to-press-congress-to-act/

good luck

I agree

Weirdly I think whenever you show up on this thread, the stock starts to go up..

that's a buying opportunity.

this soon will be back in the threes.

how long before they could get an FDA approval?

Another year and a half if everything goes well? 18 long months.

Good Luck to all:0)))

What is the future of Mind Medicine?

The shills say:

MNMD Stock 12 Month Forecast

Based on 9 Wall Street analysts offering 12 month price targets for Mind Medicine in the last 3 months. The average price target is $23.22 with a high forecast of $55.00 and a low forecast of $16.00. The average price target represents a 268.57% change from the last price of $6.30.

FOR WHAT IT IS WORTH 0:)))

NPR - Why tech bros worship psychedelics (and think you should too)
March 24, 20253:00 AM ET

https://www.npr.org/2025/03/24/1263527063/its-been-a-minute-psychedelics-tech-bros-spirituality

Will be until catalysts hit. Still bullish

Quiet in the neighborhood 

Closer by the day!

Getting ready for that phase 3 success and FDA approval. It's coming.

MindMed Appoints Matt Wiley as Chief Commercial Officer

https://www.businesswire.com/news/home/20250317335767/en/MindMed-Appoints-Matt-Wiley-as-Chief-Commercial-Officer

“Matt’s deep experience in launching multiple neuroscience and psychiatric therapeutics will be invaluable as we prepare for our first potential FDA approval of MM120 ODT,” said Rob Barrow, Chief Executive Officer of MindMed.

Sounds to good, but sometimes you get the win

This is happening... :)

U.S. Government Accountability Office - Science & Tech Spotlight: Medical Use of Psychedelics

https://www.gao.gov/products/gao-25-108021

Congressional Psychedelics Advancing Therapies (PATH) Caucus - Full PDF from Association for Prescription Psychedelics Inc.

https://www.psychedelicsrx.org/wp-content/uploads/2025/03/RESPONSE_APP_PATH-Caucus_RFI_FINAL.pdf

March 2025 - Corporate Presentation

https://d1io3yog0oux5.cloudfront.net/_b94c0eb12b83d35c5f613b13e6c7812a/mindmed/db/2288/21507/presentation/MindMed+Corporate+Presentation+March25.pdf

MindMed Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Updates

https://ir.mindmed.co/news-events/press-releases/detail/175/mindmed-reports-fourth-quarter-and-full-year-2024-financial-results-and-recent-business-updates

--First Patients Dosed in Phase 3 Voyage and Panorama studies of MM120 Orally Disintegrating Tablet (ODT) in Generalized Anxiety Disorder (GAD); 12-week topline data anticipated in 1H 2026 for Voyage and 2H 2026 for Panorama--

--On track to initiate Emerge, the first Phase 3 study of MM120 ODT in Major Depressive Disorder (MDD) in 1H of 2025--

--Raised approximately $250 million in gross proceeds through two equity financings in 2024; cash and cash equivalents of $273.7 million as of December 31, 2024, expected to fund operations into 2027 and extend at least 12 months beyond the first Phase 3 topline data readout for MM120 ODT in GAD--

--Company to host a conference call today at 8:00 a.m. EST--

Oprah - Can Psychedelics Heal Mental Trauma? With Harvard Professor Michael Pollan



https://www.youtube.com/watch?v=k9N35WCz_UI

Will Psychedelics Revolutionize Mental Health Under New Leadership?

2025-03-03 by Favio Lopez

https://smartphonemagazine.nl/en/2025/03/03/will-psychedelics-revolutionize-mental-health-under-new-leadership/

Mind Medicine (MindMed) experiences a stock price surge following Robert F. Kennedy Jr.’s appointment as Secretary of Health and Human Services.
Kennedy’s support for psychedelic therapies aligns with MindMed’s mission to innovate mental health treatment using these substances.
MindMed’s ongoing phase 3 trial on lysergide D-tartrate (LSD) for generalized anxiety disorder includes over 250 participants and is crucial for future mental health interventions.
The broader acceptance of psychedelics is challenged by stigma and regulatory obstacles, yet presents immense growth opportunities.
The psychedelic market is projected to surpass $6.8 billion by 2027, with MindMed poised at the forefront of this transformation.
The potential paradigm shift in mental healthcare, driven by political and scientific advancements, could redefine treatment approaches.

MindMed MM-120 (LSD) in GAD: Recent Research, Regulatory Developments, and Market Impact

A Primer for the Uninitiated and a Review for the Accustomed
Recent LSD Research in Mental Health and GAD

Growing Evidence of LSD’s Therapeutic Potential: In the past two months, several studies have highlighted LSD’s promise for treating anxiety and other mental health disorders. Notably, a 2023 clinical trial using two guided LSD sessions (200 µg each) reported lasting reductions in anxiety and depression, with 33% of participants in anxiety remission one year post-treatment?

psychiatryinstitute.com. This suggests that LSD, when combined with therapy, can produce sustained relief from anxiety symptoms. More recently, MindMed’s own Phase 2b trial in generalized anxiety disorder (GAD) demonstrated robust efficacy from a single 100 µg dose of LSD (MM-120) without any psychotherapy?psychiatryinstitute.com. In that trial, patients receiving MM-120 showed rapid, statistically significant improvements in anxiety (Hamilton Anxiety Rating Scale) versus placebo, with 65% achieving a clinical response and 48% reaching remission by 12 weeks?psychiatryinstitute.com. These findings – achieved with pharmacotherapy alone – underscore LSD’s potential as a novel anxiolytic.

Comparisons to Microdosing and Other Indications: While microdosing LSD has been popularized anecdotally, rigorous studies have so far failed to show clear benefits. For example, controlled trials of repeated low-dose LSD found no significant improvements in mood or cognition compared to placebo?

psypost.org. This contrasts with the marked improvements seen with full psychedelic doses in therapeutic settings. Beyond anxiety, researchers are also exploring LSD for other conditions: MindMed itself is planning a Phase 3 trial (“Emerge”) of MM-120 in major depressive disorder, and other startups like MindBio are testing LSD microdoses in depression?greenmarketreport.com?biospace.com. Overall, recent research signals that LSD – at carefully controlled, therapeutically relevant doses – can produce meaningful mental health benefits, especially in hard-to-treat conditions like GAD, whereas microdosing alone remains unproven.
FDA’s Evolving Stance on Psychedelic Drug Approvals

Cautious Openness and New Guidance: The U.S. Food and Drug Administration (FDA) has in the last couple of years shown a cautious but growing openness toward psychedelic therapies. In June 2023, the FDA released its first draft guidance for clinical trials with psychedelics, acknowledging the “therapeutic potential” of drugs like psilocybin, LSD, and MDMA and expressing willingness to work with developers?

foley.com. This guidance highlights unique trial design challenges (e.g. blinding, expectancy effects) and stresses the need for rigorous methodologies, but its issuance was itself a signal that the FDA is preparing for psychedelic drug development. The agency has also granted Breakthrough Therapy Designations – an expedited development status – to several psychedelic-based treatments, including psilocybin for depression, MDMA for PTSD, and most recently MindMed’s LSD-derived MM-120 for GAD?psychiatryinstitute.com. Such designations indicate that early evidence is very promising and that the FDA will prioritize guidance on these programs. As one commentator noted, having LSD join MDMA and psilocybin as a Breakthrough therapy shows regulators see these as “hopeful treatment[s] for mental health conditions”?psychiatryinstitute.com.

Regulatory Rigor and Recent Policy Signals: Despite this optimism, the FDA’s stance remains appropriately rigorous. No psychedelic has yet been fully approved, and the FDA has made clear that Breakthrough status does not mean automatic approval?

psychiatryinstitute.com. A recent high-profile case underscored the FDA’s insistence on solid evidence: In 2024 the FDA rejected an NDA for MDMA-assisted therapy in PTSD, issuing a Complete Response Letter that requested an additional Phase 3 trial?hklaw.com. The agency agreed with advisors that the prior trials had not definitively proven efficacy, partly due to issues like patients correctly guessing they were on the drug (unblinding) and concerns about adverse events?hklaw.com. This decision, coming despite MDMA’s Breakthrough designation and strong Phase 3 results, illustrates the FDA’s commitment to traditional approval standards (statistically robust, well-controlled trials) for psychedelics. In short, recent FDA actions and policies signal guarded support: the door is open for psychedelic therapies, but sponsors must meet the same high bar for safety and efficacy as any new drug. This balanced stance directly influences how MindMed and peers design their trials and interact with regulators.
MindMed’s MM-120 Clinical Progress with the FDA

Phase 2 Success and FDA Alignment: MindMed’s lead candidate MM-120 (a pharmaceutically optimized form of LSD) has progressed rapidly, buoyed by positive clinical data and constructive FDA engagement. In late 2023, MindMed announced that its Phase 2b trial in GAD met its primary endpoint, with a single dose of MM-120 (100 µg) producing a 7.6-point greater reduction in anxiety scores (HAM-A) at 4 weeks compared to placebo (p

You'll get another chance. :)

Should've sold the 10's

Buy the dip

Rah!

Onward and upward.

MNMD announced that it will host a live webcast at 8:00 a.m. ET on Thursday, March 6, 2025 to report financial results for the fourth quarter and year ended December 31, 2024, and discuss recent business updates.

Agreed but not overly concerned - we have a heck of a year coming